{"nctId":"NCT00885742","briefTitle":"A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency","startDateStruct":{"date":"2009-08"},"conditions":["Factor XIII Deficiency"],"count":41,"armGroups":[{"label":"FXIII","type":"EXPERIMENTAL","interventionNames":["Biological: FXIII Concentrate (Human)"]}],"interventions":[{"name":"FXIII Concentrate (Human)","otherNames":["Fibrogammin-P"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent/assent for study participation obtained before undergoing any study-specific procedures\n* Documented congenital FXIII deficiency which requires prophylactic treatment with a FXIII containing product.\n* Males and females of any age with congenital FXIII deficiency\n* Received full hepatitis B vaccination and/or is hepatitis B surface antibody positive\n\nExclusion Criteria:\n\n* Diagnosis of acquired FXIII deficiency\n* Administration of a FXIII-containing product, including blood transfusions or other blood products within 4 weeks prior to the planned Day 0\n* Any known congenital or acquired coagulation disorder other than congenital FXIII deficiency\n* Known or suspected to have antibodies towards FXIII\n* Use of any other investigational medicinal product within 4 weeks prior to the Baseline Visit (Day 0)\n* Known Positivity for human immunodeficiency virus (HIV) or a positive result for HIV at the Screening Visit of this study or the FXIII study 2002 (NCT00883090).\n* Serum aspartate transaminase (AST) or serum alanine transaminase (ALT) concentration \\>2.5 times the upper limit of normal at the Screening Visit of this study or at the Day 56 Visit of Factor XIII Study BI71023\\_2002 (NCT00883090)\n* Fibrinogen level less than 85% of the lower limit of normal at the Screening Visit of this study or the Factor XIII Study BI71023\\_2002 (NCT00883090)\n* Active bleeding ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 and/or ≥ moderate between the Screening and Baseline Visits\n* Pregnant or breast-feeding\n* Intention to become pregnant during the course of the study\n* Female subjects of childbearing potential not using, or not willing to use, a medically reliable method of contraception for the entire duration of the study\n* Suspected inability (e.g., language problems) or unwillingness to comply with study procedures or history of noncompliance","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Incidence of Spontaneous Bleeding Events Requiring Treatment (Treatment is Defined as Administration of a FXIII-Containing Product to Treat the Bleeding Event)","description":"The number of subjects requiring treatment with a Factor XIII-containing product to treat a spontaneous bleeding event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Association of the Incidence of Spontaneous Bleeding Events Requiring Treatment and FXIII Activity Trough Levels","description":"P-value determined from Generalized Estimating Equation (GEE) model parameter estimates with bleeding as the response variable and FXIII activity trough level as the explanatory variable.","classes":[]},{"type":"SECONDARY","title":"Adverse Events","description":"Number of subjects with any treatment-emergent adverse event (AE), treatment-related AE or serious AE (SAE). Treatment related AEs are defined as AEs whose relationship to study treatment is related, or possibly related, and AEs with missing relationship.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Peak FXIII Concentration at Steady State","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.968","spread":"0.2292"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.045","spread":"0.3825"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.962","spread":"0.2306"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.983","spread":"0.2633"}]}]}]},{"type":"SECONDARY","title":"Trough FXIII Concentration at Steady State","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.132","spread":"0.0305"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.136","spread":"0.0362"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.130","spread":"0.0254"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.150","spread":"0.1138"}]}]}]},{"type":"SECONDARY","title":"Time to Peak Concentration","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.632","spread":"0.2296"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.615","spread":"0.1978"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.623","spread":"0.2350"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.636","spread":"0.2328"}]}]}]},{"type":"SECONDARY","title":"Incremental Recovery","description":"Incremental recovery (U/mL/U/kg) is defined as maximum (peak) FXIII activity (U/mL) obtained after infusion, per dose of (U/kg) infusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.021","spread":"0.0059"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.023","spread":"0.0104"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.021","spread":"0.0056"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.020","spread":"0.0056"}]}]}]},{"type":"SECONDARY","title":"Achievement of Trough Factor XIII Levels of 5% or Higher.","description":"Number of subjects with Factor XIII level ≥ 5% before infusion at Week 12, Week 24, Week 36 and Week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":41},"commonTop":["Upper respiratory infection","Fever","Cough","Fall","Nasal congestion"]}}}